Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025 - 2026)
Oramed Pharmaceuticals (ORMP) reported Non-Current Deferred Tax Liability of $17.7 million for Q1 2026, up 124.33% quarter-over-quarter from $7.9 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Oramed Pharmaceuticals has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $17.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $17.7 million; the trailing twelve-month figure through Mar 2026 stood at $17.7 million (changed N/A YoY), and the FY2025 full-year result was $7.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $17.7 million, up from $7.9 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $17.7 million in Q1 2026, with the low at $7.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Oramed Pharmaceuticals | 151.47 Mn | 133.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.75 Mn |
| Mar 31, 2026 | 17.75 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Sep 30, 2025 | 7.92 Mn |
| Sep 30, 2025 | 7.92 Mn |